Biology:NGR-hTNF (antitumor recombinant protein)

From HandWiki
Revision as of 01:10, 10 February 2024 by JTerm (talk | contribs) (simplify)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

}}

NGR-hTNF is an experimental antitumor drug designed to act on tumor blood vessels.[1][2][3] It is currently undergoing Phase III clinical trials [4] for treatment of malignant pleural mesothelioma caused by exposure to asbestos.[5][6][7] NGR-hTNF is also being investigated, alone or in combination with chemotherapy,[8] on four different solid tumors[9][10] in four other randomized Phase II trials.[11]

NGR-hTNF is a recombinant protein derived from the fusion between peptide CNGRCG [12] and human tumor necrosis factor alpha [13] (TNFα).[14][15] Once it has reached the tumor, NGR-hTNF performs its antitumor action.[16] The Phase III (NGR015) [17] clinical trial is in progress in 35 clinical centers in Europe (Italy, UK, Ireland, Poland and Belgium), USA, Canada and Egypt. NGR-hTNF is the only drug being tested in Phase III trials [18] for the treatment of relapsed Mesothelioma, and has been granted Orphan Drug designation both in Europe and USA. [19][20]

References

  1. ↑ "NGR hTNF among the Top 10". http://www.biotechnology-europe.com. http://www.biotechnology-europe.com/news/news%20by%20company/Molmed/15.10.2010%20NGR-hTNF%20among%20the%20Top%2010%20most%20interesting%20oncology%20projects%20to%20watch.html. 
  2. ↑ "Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients". British Journal of Cancer 107 (1): 37–42. Jun 2012. doi:10.1038/bjc.2012.233. PMID 22644293. 
  3. ↑ "MolMed a New Patent on Its Anticancer Drug NGR-hTNF". http://finance.yahoo.com. https://finance.yahoo.com/news/european-patent-office-grants-molmed-053300980.html. 
  4. ↑ "MolMed PhaseIII Trial on NGRhTNF". http://www.biotechnology-europe.com. http://www.biotechnology-europe.com/news/news%20by%20company/Molmed/2012/13.12.2012%20MolMed%20completes%20enrolment%20in%20pivotal%20Phase%20III%20trial%20of%20NGR-hTNF%20in%20relapsed%20mesothelioma%20patients.html. 
  5. ↑ "Multidisciplinary treatment". Oncologist 12 (7): 850–63. July 2007. doi:10.1634/theoncologist.12-7-850. PMID 17673616. 
  6. ↑ "MolMed starts Phase III of NGRhTNF". http://www.mesotheliomacenter.org/mesothelioma-news/2010/04/20/molmed-starts-phase-iii-trial-of-ngr-htnf-in-mesothelioma/. 
  7. ↑ Multidisciplinary treatment of malignant pleural mesothelioma. Oncologist., 2007, pp. 12:850–863 
  8. ↑ "Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration", Journal of Clinical Investigation 110 (4): 110:475–482, 2002, doi:10.1172/jci0215223, PMID 12189241 
  9. ↑ Phase II study of NGR-hTNF in combination with doxorubicina in relapsed ovarian cancer patients. Br J Cancer, 2012-06-26, pp. 107(1):37–42 
  10. ↑ "Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractary solid tumors. Clin Cancer Res", Clin. Cancer Res. 17 (7): 107(1):37–42 1;17 (7): 1964–72, Apr 2011, doi:10.1158/1078-0432.CCR-10-1376, PMID 21307147 
  11. ↑ "MolMed new data ngr htnf". https://www.drugs.com. https://www.drugs.com/clinical_trials/molmed-presents-new-data-four-clinical-trials-ngr-htnf-european-multidisciplinary-cancer-congress-12421.html. 
  12. ↑ "Safety and anticancer activity of low dose regimen of NGR-hTNF". www.molmed.com. http://www.molmed.com/sites/default/files/uploads/publications/1057/asco_2007_p3540_ngr.pdf. 
  13. ↑ Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol, 2000, pp. 18:1185–1190 
  14. ↑ Curnis, Flavio; Sacchi, Angelina; Corti, Angelo (2002). "Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration". Journal of Clinical Investigation 110 (4): 475–482. doi:10.1172/jci0215223. PMID 12189241. 
  15. ↑ Fiers. Biologic therapy with TNF: preclinical studies. In: Company JL, ed. Biologic therapy of cancer: principles and practice, Philadelphia: (ed V De Vita, S Hellman and S Rosenberg (edts))., pp. 1995:295 
  16. ↑ "Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors". Clinical Cancer Research 17 (7): 1964–72. Apr 2011. doi:10.1158/1078-0432.CCR-10-1376. PMID 21307147. 
  17. ↑ "MolMed Completes Enrolment in Pivotal Phase III". http://www.evaluategroup.com/. http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=369828. 
  18. ↑ "MolMed starts Phase III trial of NGR-hTNF in mesothelioma". http://www.molmed.com/sites/default/files/uploads/press-releases/1291-molmed_starts_phase_iii_trial_of_ngr-htnf_in_mesothelioma/1291_1337707610.pdf. 
  19. ↑ "US FDA Grants Orphan Status to Mesothelioma Drug". http://www.asbestos.net/newsroom/news/2008/09/23/us-fda-grants-orphan-status-to-mesothelioma-drug. 
  20. ↑ "MolMed Expands Phase III Trial of NGR-hTNF for the Treatment of Mesothelioma in the United States". https://finance.yahoo.com/news/MolMed-Expands-Phase-III-iw-3171791129.html. 

External links



Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:NGR-hTNF_(antitumor_recombinant_protein)&oldid=3492525"